| Literature DB >> 29079988 |
Yi-Fan Yin1,2, Yang Guo1,2, Wen-Ding Song1,2, Xiao-Chuan Duan1,2, Xiu-Chai Zheng1,2, Ting Zhong1,2, Shuang Zhang1,2, Xin Yao1,2, Mei-Qi Xu1,2, Qiang Zhang1,2,3, Xuan Zhang4,5.
Abstract
Here, the mesoporous silica (Sylysia 350) was selected as mesoporous material, hydroxypropyl methylcellulose (HPMC) was selected as crystallization inhibitor, and febuxostat (FBT) was selected as model drug, respectively. The FBT-Sylysia-HPMC nanomatrix (FBT@SHN) was prepared. The characteristics of FBT@SHN were investigated in vitro and in vivo. Our results indicated that the FBT in FBT@SHN was in amorphous form. The solubility and dissolution of FBT in FBT@SHN were significantly increased. The oral bioavailability of FBT in FBT@SHN was greatly improved 5.8-fold compared with that in FBT suspension. This nanomatrix could be used as a drug delivery platform for improving the oral bioavailability.Entities:
Keywords: HPMC; febuxostat; nanomatrix; oral bioavailability
Mesh：
Substances：
Year: 2017 PMID： 29079988 DOI： 10.1208/s12249-017-0905-z
Source DB: PubMed Journal: AAPS PharmSciTech ISSN： 1530-9932 Impact factor: 3.246